PCID2

Across TCGA pan-cancer cohorts, PCID2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PCID2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where PCID2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PCID2 is over-expressed in tumor.

COAD, HNSC, and PDAC are the cancer types where PCID2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCID2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+0.341	<.001	12	view →
HNSC	Female	All	+0.345	<.001	11	view →
PDAC	Male	II,III,IV	+0.365	<.001	8	view →
LUAD	Male	All	+0.210	<.001	8	view →
LSCC	Male	II,III,IV	+0.361	<.001	7	view →
CCRCC	Male	All	+0.077	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PCID2–COAD

Open the COAD breakdown →